Loading…
← CockpitCompetitor Analysis › 600226.SS Zhejiang Hengtong Holding Co., Ltd Class AOpen in the cockpit ↗

Zhejiang Hengtong Holding Co., Ltd Class A600226.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Zhejiang-based holding company classified under health care/biotechnology; specific business segments not established from available knowledge.

Momentum laggard 15
Mkt cap
$1.64B
US dollars, full cap
Free float
59%
of shares outstanding
$/day
$34.5M
20-day average traded
Fwd P/E
27.6×
forward earnings
ROIC−WACC
-6.3 pp
WACC 7.8%
Hurdle
n/a
no reverse DCF
Next earnings
160 days
27 Apr 2027
Close · CNYCN¥3.88
1D+1.0%
1W-9.8%
1M-15.3%
3M-36.3%
6M-31.2%
YTD-27.2%
1Y-5.4%
ATR %5.0%
52w lowhigh67.6% off high

What Zhejiang Hengtong does

Zhejiang-based holding company classified under health care/biotechnology; specific business segments not established from available knowledge.

Where it sits in the supply chain

  • Health Care
  • Biotechnology

Moat: none

Headquarters: Zhejiang, China · Employees: 1,046

Zhejiang Hengtong at a glance

Size Zhejiang Hengtong (600226.SS) is a China Health Care company (Biotechnology) with a market value of $1.64B, the 1402nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥3.88 on 18 Nov 2026.

Performance Over six months the shares fell 31.2%, against -3.7% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 19 in its peer set.

Growth Revenue grew 71.0% over the last twelve months (peer median +19.3%); the operating margin is -0.2% (peer median -18.1%).

Valuation It trades at 27.6× forward earnings against a peer median of 22.6× (4th most expensive of 8).

Capital Return on invested capital runs 6.3 points below its cost of capital (7.8% WACC).

Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026Peer median 95600226.SS 67
Six months, rebased to 100: Zhejiang Hengtong against the median of its 20 peers (local-currency closes).

Zhejiang Hengtong financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.88BCN¥1.85BCN¥1.33BCN¥646MCN¥602M
Revenue growth—+40%+105%+7%—
Gross profitCN¥336MCN¥111MCN¥131MCN¥128MCN¥70.3M
EBITDAn/aCN¥102MCN¥88.6MCN¥59.3M-CN¥52.8M
Net incomeCN¥145MCN¥201MCN¥189MCN¥166MCN¥482M
Free cash flow-CN¥210M-CN¥445M-CN¥5.69M-CN¥406M-CN¥155M
Capital expenditureCN¥83.7MCN¥297MCN¥132MCN¥396MCN¥257M
Total debtCN¥2.20BCN¥1.03BCN¥571MCN¥320MCN¥116M

Quarterly statements and history in the cockpit →

Zhejiang Hengtong competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%ANIPALVO6882226949PPGN145020VIRNRIXSTOKPGENKLRARXRXKRSA688319688046ZBIO087010600226.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Hengtong is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%20×40×60×ANIPALVO688222PPGN145020PGEN688046600226.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Hengtong is the large dot.

Zhejiang Hengtong competitors and peer comparison

How Zhejiang Hengtong compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Hengtong against its 20 peers (data as of 18 Nov 2026)
Measure600226.SSPeer medianRank in peer set
1-month return-15.3%-7.5%6th lowest of 20
6-month return-31.2%-3.7%4th lowest of 19
Distance from 52-week high-67.6%-39.8%2nd lowest of 21
Revenue growth (TTM)+71.0%+19.3%5th highest of 19
Operating margin-0.2%-18.1%10th highest of 19
Forward P/E27.6×22.6×4th most expensive of 8
ROIC minus cost of capital-6.3 pp-4.0 pp7th lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zhejiang Hengtong 600226.SSChina$1.64B-31%+71%0%27.6×n/an/a
ANI Pharmaceuticals ANIPUnited States$1.62B-13%+26%15%7.5×-7.6%+33.5%
Alvotech ALVOUnited States$1.62B+38%-14%12%22.6×n/an/a
Hitgen 688222.SSChina$1.62B-3%+42%27%73.2×33.2%+16.8%
PELL Bio-Med Technology 6949.TWTaiwan$1.62B+28%+8%-1,463%n/an/an/a
PolyPeptide PPGN.SWSwitzerland$1.61B+7%+22%7%52.1×n/an/a
Hugel 145020.KSSouth Korea$1.69B-30%+17%38%18.1×-12.1%+15.0%
Vir Biotechnology VIRUnited States$1.57B+3%+1,696%-70%n/an/an/a
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%n/an/an/a
Stoke Therapeutics STOKUnited States$1.75B-12%-86%-913%n/an/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%7.3×n/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Recursion Pharmaceuticals RXRXUnited States$1.76B-5%+56%-725%n/an/an/a
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%n/an/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%n/an/an/a
GemPharmatech 688046.SSChina$1.78B+39%+25%22%51.9×33.0%+24.8%
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Zenas BioPharma ZBIOUnited States$1.79B+35%-27%-2,748%n/an/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%n/an/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%n/an/an/a
Lycia Therapeutics LYCAUnited States$1.81Bn/a-55%-593%n/an/an/a

Questions

Which companies are Zhejiang Hengtong's closest peers?
The cockpit's peer set: ANI Pharmaceuticals (ANIP), Alvotech (ALVO), Hitgen (688222.SS), PELL Bio-Med Technology (6949.TW), PolyPeptide (PPGN.SW), Hugel (145020.KS), Vir Biotechnology (VIR), Nurix Therapeutics (NRIX).
Is Zhejiang Hengtong expensive compared with its peers?
On forward p/e it trades at 27.6× against a peer median of 22.6×, 4th most expensive of 8 in its peer set.
How has Zhejiang Hengtong stock performed?
Over six months to 18 Nov 2026 the shares returned -31.2% against -3.7% for the median peer; over one year -5.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.